Back to Journals » International Medical Case Reports Journal » Volume 14

Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine–Gass Syndrome

Authors Marques JH, Abreu AC, Silva N, Meireles A, Pessoa B, Melo Beirão J

Received 1 December 2020

Accepted for publication 13 January 2021

Published 26 February 2021 Volume 2021:14 Pages 127—132


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser

João Heitor Marques,1 Ana Carolina Abreu,1 Nisa Silva,1 Angelina Meireles,1,2 Bernardete Pessoa,1,2 João Melo Beirão1,2

1Serviço de Oftalmologia, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal

Correspondence: João Heitor Marques
Centro Hospitalar Universitário do Porto, Serviço de Oftalmologia, Largo do Prof. Abel Salazar, Porto, 4099-001, Portugal
Tel +351913680726
Email [email protected]

Background: Cystoid macular edema (CME) due to Irvine–Gass syndrome (IGS) is one of the common causes of painless visual impairment post-cataract extraction. The treatment of recurrent cases remains unstandardized.
Objective: To evaluate the effectiveness and safety of fluocinolone acetonide intravitreal implant (0.2 μg/day; ILUVIEN®) in the off-label treatment of recurrent CME due to IGS.
Methods: Retrospective 36-month case series in the Ophthalmology Department of Centro Hospitalar Universitário do Porto, Portugal. Consecutive eyes of patients with recurrent cystoid macular edema due to Irvine–Gass syndrome who underwent a single intravitreal injection of fluocinolone acetonide intravitreal implant were included. Best-corrected visual acuity (logMAR), central macular thickness (μm) and safety (intraocular pressure, mmHg) at baseline and at 6, 12, 24 and 36 months post-administration of the fluocinolone acetonide intravitreal implant were recorded.
Results: Five eyes from three patients were included. The duration of cystoid macular edema was 67.8± 25.9 months and all five eyes received more than 2 intravitreal injections of a corticosteroid (triamcinolone and/or dexamethasone implant) prior to fluocinolone acetonide intravitreal implantation. At baseline (median – interquartile range), best-corrected visual acuity was 0.3– 0.3; central macular thickness was 492.0– 38.0; and intraocular pressure was 16.0– 0. By Month 36, best-corrected visual acuity was 0.4 − 0.3; central macular thickness was reduced to 369.0– 324.0 and intraocular pressure was 17.0– 3.0. Four of five eyes had increased intraocular pressure and were managed with intraocular pressure-lowering eye drops.
Conclusion: We report improved functional and anatomical outcomes after treatment with fluocinolone acetonide intravitreal implant, indicating its use as a therapeutic alternative in recurrent cases of cystoid macular edema due to Irvine–Gass syndrome. Additionally, in eyes with suboptimal response to intravitreal therapies, fluocinolone acetonide intravitreal implant may provide longer recurrence-free periods with reduced treatment burden.

Keywords: cataract surgery, Irvine–Gass syndrome, cystoid macular edema, pseudophakic cystoid macular edema, fluocinolone acetonide

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]